Society of Nuclear Medicine

SHERPA: Unknown

People

  1. Humm
    Humm
  2. Zanzonico
    Zanzonico
  3. Schoder
    Schoder
  4. Lewis
    Lewis
  5. O'Donoghue
    O'Donoghue
  6. Blasberg
    Blasberg
  7. Morris
    Morris
  8. Kesner
    Kesner
  9. Carter
    Carter
  10. Scheinberg
    Scheinberg

Groups

  1. Radiology, Department of (703)
  2. Molecular Imaging and Therapy Service (577)
  3. GSK Faculty (478)
  4. Sloan Kettering Institute Faculty (388)
  5. Molecular Pharmacology and Chemistry Program Faculty (383)
  6. Medical Physics (308)
  7. Sloan Kettering Institute Postdocs (271)
  8. Department of Medicine (217)
  9. Radiochemistry and Imaging Sciences Service (213)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (183)
Search Within
Formats
  1. Journal Article (469)
  2. Meeting Abstract (422)
  3. Review (32)
  4. Editorial (25)
  5. Miscellaneous (7)
  6. Correspondence (6)
  7. Guidelines (3)
  8. Conference Paper (2)
  9. Research Letter (1)
Groups
  1. Radiology, Department of (703)
  2. Molecular Imaging and Therapy Service (577)
  3. GSK Faculty (478)
  4. Sloan Kettering Institute Faculty (388)
  5. Molecular Pharmacology and Chemistry Program Faculty (383)
  6. Medical Physics (308)

More Groups

People
  1. Steven Larson (294)
  2. John Humm (116)
  3. Pat Zanzonico (99)
  4. Ronald Finn (99)
  5. Heiko Schoder (97)
  6. Jason Lewis (90)

More People

Years
  1. 2025 (33)
  2. 2024 (51)
  3. 2023 (54)
  4. 2022 (24)
  5. 2021 (38)
  6. 2020 (47)

More Years

Publications
  1. Journal of Nuclear Medicine (967)

Results (967)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of FDG PET imaging for expanding patient eligibility and measuring treatment response in a multicenter genome-driven basket trial
    Meeting Abstract

    Ulaner, G.; Saura, C.; Piha-Paul, S.; Mayer, I.; Quinn, D.; Stone, B.; Mann, G.; Meric-Bernstam, F.; Solit, D.; Hyman, D.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • 89Zr-trastuzumab PET/CT for prediction of response to HER2-targeted therapy in patients with HER2 mutant lung cancer: An exploratory phase 2 trial
    Meeting Abstract

    Ulaner, G.; Offin, M.; Scaltriti, M.; Myers, M.; Venkatesh, A.; Panora, E.; Kris, M.; Rudin, C.; Arcila, M.; Lyashchenko, S.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Histologically-confirmed diagnostic efficacy of (18)F-rhPSMA-7 positron emission tomography for N-staging of patients with high risk primary prostate cancer
    Meeting Abstract

    Kroenke, M.; Wurzer, A.; Schwamborn, K.; Ulbrich, L.; Jooay, L.; Maurer, T.; Horn, T.; Kropf, S.; Haller, B.; Wester, H.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Selection and radiolabeling of bicyclam analogues for Imaging CXCR4 expression in gliomas (GBM) and primary CNS lymphoma (PCNSL)
    Meeting Abstract

    Maeda, M.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Post-treatment 18F-FDG PET/CT surveillance for detection of recurrence in stage III Merkel cell carcinoma
    Meeting Abstract

    Mahajan, S.; Barker, C.; Pandit-Taskar, N.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • PET imaging of recurrent brain tumors using (18)F-FACBC
    Meeting Abstract

    Michaud, L.; Beattie, B.; Lassman, A. B.; Zanzonico, P.; Akhurst, T. J.; Ronald, D. F.; Audrey, M.; Larson, S.; Schoder, H.; Weber, W. A.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Optimizing dosimetry imaging in high-dose radioimmunotherapy using the novel, anti-CD45 re-induction and targeted conditioning agent iodine (131)I apamistamab [Iomab-B] in patients 55 years or older with active, relapsed or refractory acute myeloid leukemia (SIERRA phase III trial)
    Meeting Abstract

    Pandit-Taskar, N.; Passalaqua, S.; Wiseman, G.; Avril, N.; Yap, W.; Chen, M. K.; Wagner, R.; Natwa, M.; Chasen, B.; Lamonica, D.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Results from the OSPREY trial: A Prospective phase 2/3 multi-center study of (18)F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy
    Meeting Abstract

    Rowe, S.; Gorin, M.; Pienta, K.; Siegel, B.; Carroll, P.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M.; Alva, A.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Prognostic value of (18)F-FDG PET/CT imaging in recurrent salivary gland cancers
    Meeting Abstract

    Nakajima, R.; Patel, S. G.; Schoder, H.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Ultrasmall silica nanoparticle platforms for improved small molecular inhibitor delivery and efficacy
    Meeting Abstract

    Madajewski, B.; Chen, F.; Yoo, B.; Ma, K.; Turker, M.; Zhang, L.; Zanzonico, P.; Wiesner, U.; Bradbury, M.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save

    • Society of Nuclear Medicine – authorized name for: